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Introduction 
When evaluating the design of clinical trials which assess 
the pharmacological, pharmacokinetic and clinical efIects 
of different inhalation therapies, it is important to realize 
exactly what each type of study design aims to show. 
111 vitro and standardized in viva inhalation studies have a 
great sensitivity in detecting differences in the pharmaco- 
logical and pharmacokinetic profile of different drugs and 
inhalers, especially with regard to particle size and 
deposition profile. However, these studies are often con- 
ducted under highly artificial conditions, which are quite 
different from everyday clinical procedures, where several 
other factors (including compliance, ease of inhaler use, 
convenience, price and prescribed dose) may be equally 
important. 
With this in mind, it would seem pertinent to consider 
what such studies might tell us about the comparative 
effects of different inhalers and drugs. For example: 
l Does an increase in lung deposition always lead to an 
increase in clinical effect? 
. I f  so, is there a linear relationship between increase in 
lung deposition and the increase in clinical effect? 
. Are the results obtained with one class of drug (for 
example P-agonists) also valid for other classes of drug 
(steroids)? 
Normally, inhalation clinical trials are less sensitive than 
the standardized irl virro or in Go laboratory studies with 
regard to their ability to detect differences between different 
drugs (Fig. 1). However, clinical studies are more in tune 
with actual clinical practice, and so their predictive value of 
how the drugs or inhalers will perform in ‘real life’ 
increases. 
Drug deposition and clinical effect 
Olsson (1) has shown a linear relationship between lung 
deposition and particle size of different dry powder 
inhalers. He found that the percentage of nominal dose 
deposited in the lungs was directly proportional to the 
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proportion of the nominal dose that was delivered as 
fine particles (<5/tm). These data suggest that under 
controlled, standardized laboratory conditions there is a 
good correlation between in vitro and in viva results. 
I f  this is taken one step further there are also studies 
which suggest that there is a good correlation between lung 
deposition and clinical effect. Borgstrom et al. (2) measured 
lung deposition with two doses of terbutaline (25Opg and 
500/(g) from Turbohaler and pMD1. At each dose there 
was higher (approximately two times) lung deposition from 
Turbohaler compared to pMD1. When the bronchodilation 
was measured, the response to the 25Opg pMD1 was 
significantly less than the response to 25Opg Turbohaler; 
thus a doubling of lung deposition was associated with a 
doubling of clinical effect. Several other studies have 
confirmed this difference in clinical effect between these 
two inhalers. However, other studies have failed to confirm 
this difference. There may be many reasons for this, the 
most important being the doses compared. Correct dose 
selection is crucial in drug or inhaler comparisons. 
Importance of dose and 
dose-response considerations 
Figure 2 illustrates the dose-response relationship of two 
drugs or inhalers (A and B). In this example there is no 
difference in effect between a IOOpg dose of drug A and 
800 pg of B. This could infer that drug or inhaler A is much 
better than B. However, looking at the illustration once 
again, the conclusion could also be reached that 100 pg and 
400,~g were equi-effective, emphasizing that single measure- 
ments do not allow conclusions to be drawn regarding the 
relative potency of inhalers or drugs. For this to be done it 
is necessary to have the full dose-response curve for each 
inhaler or drug. 
However, even when the full dose-response curve data 
are available, the relationship between two different 
inhalers or drugs can be very complex, depending upon 
where on the dose-response curve comparisons are made. 
If, for example, the two dose-response curves are not 
parallel, the interpretation becomes quite complex. Thus, at 
line C in Fig. 2, approximately 7Opg of one drug is 
equivalent to approximately 220 /lg of the other (a relative 
potency factor of 3). However, lower down on the response 
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FIG. 2. Study designs: dose-response relationships. 
curve (line D) the relative potency factor would be less 
than 2. 
As mentioned earlier, a two-fold difference was seen 
between the two inhalers when a terbutaline dose of 250 pg 
was studied. However, if SOOpg of pMDI and 5OOpg 
Turbohaler had been compared in that study, the conclu- 
sions would have been completely different. As can be seen 
from Fig. 3, there was no difference between pMD1 and 
Turbohaler devices at this dose, and so a doubling in lung 
deposition had no apparent effect on the clinical effect 
because the doses studied were too high. 
Importance of study design 
In a dose-response study comparing budesonide Turboha- 
ler and metered dose inhaler in children with a reversibility 
of approximately 25% (3) there were no statistically 
significant differences between Turbohaler and MD1 across 
the dose range. Thus, the two inhalation devices were 
assessed to be equipotent (Fig. 4). 
However, a different conclusion was reached when these 
two devices were assessed using an alternative study design 
(4). Here the children were asked to exercise, which led to a 
marked fall in their lung function; the induced broncho- 
constriction was then treated either with a terbutaline 
pMD1 or Turbohaler. Signific-ant differences were seen in 
clinical effect between the two inhalers suggesting that they 
were not equipotent. The latter study design is more likely 
to represent the situation in normal, day to day, clinical 
practice. 
How do these data relate to steroids? 
The situation with steroids is even more complex because 
the dose-response curve of different outcome parameters 
differs. Normally, low doses of inhaled steroids produce 
marked effects on the most commonly measured outcomes 
such as peak flow, lung functions, symptoms, rescue /Is- 
agonist use and quality of life. Often a doubling in steroid 
dose does not result in any significant improvement in these 
outcomes (5) (Fig. 5). This means that studies which use 
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FIG. 4. Deposition vs. efficacy (adapted from Ref. 5). --a-: Turbohaler; -m-: MDI. 
these outcomes will run a great risk of missing important 
differences between inhalers. 
However, if other outcomes are used differences may be 
easier to detect. Thus, even if no differences were seen 
between 100 pg and 400 pg of budesonide in effect on peak 
expiratory flow rates, statistically significant differences 
between 1OOpg and 2OOpg budesonide, as well as between 
2OOpg and 4OOpg budesonide were seen in protection 
against fall in FEVt after exercise. 
Finally, although effectiveness studies have a low 
sensitivity they may sometimes confirm the findings in 
controlled in vilro and in viva studies. Thus, in a 3-year dose 
titration study, budesonide Turbohaler was found to 
produce somewhat better clinical control than a 50% 
higher dose of budesonide delivered by pMDI (6). 
Summary 
0 Normally an increase in lung deposition leads to an 
improved clinical effect. 
l An increase in clinical effect should be substantial 
(two-fold or greater) in order to be detected even in 
carefully conducted clinical trials. 
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FIG. 5. Budesonide dose-response and clinical efficacy (adapted from Ref. 5). 
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